Evan David Seigerman
Stock Analyst at BMO Capital
(3.33)
# 1,007
Out of 5,132 analysts
54
Total ratings
51.06%
Success rate
4.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Upgrades: Outperform | $82 → $130 | $121.41 | +7.08% | 5 | Dec 18, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $725 → $850 | $803.17 | +5.83% | 9 | Dec 4, 2025 | |
| AMGN Amgen | Maintains: Outperform | $335 → $372 | $369.19 | +0.76% | 5 | Dec 3, 2025 | |
| NVO Novo Nordisk | Maintains: Market Perform | $50 → $46 | $49.57 | -7.20% | 8 | Nov 25, 2025 | |
| REPL Replimune Group | Upgrades: Market Perform | $2 → $11 | $7.98 | +37.84% | 5 | Nov 3, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $215 → $240 | $231.50 | +3.67% | 8 | Sep 12, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $17.37 | +49.68% | 2 | Jun 12, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $22.03 | +27.10% | 2 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $11.65 | -14.16% | 1 | May 5, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $70 → $112 | $55.95 | +100.18% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $70.07 | +42.71% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $27.58 | +30.53% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $5.68 | -47.18% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $1,040.00 | -61.92% | 1 | Sep 6, 2022 |
Merck & Co.
Dec 18, 2025
Upgrades: Outperform
Price Target: $82 → $130
Current: $121.41
Upside: +7.08%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Outperform
Price Target: $725 → $850
Current: $803.17
Upside: +5.83%
Amgen
Dec 3, 2025
Maintains: Outperform
Price Target: $335 → $372
Current: $369.19
Upside: +0.76%
Novo Nordisk
Nov 25, 2025
Maintains: Market Perform
Price Target: $50 → $46
Current: $49.57
Upside: -7.20%
Replimune Group
Nov 3, 2025
Upgrades: Market Perform
Price Target: $2 → $11
Current: $7.98
Upside: +37.84%
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215 → $240
Current: $231.50
Upside: +3.67%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $17.37
Upside: +49.68%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $22.03
Upside: +27.10%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $11.65
Upside: -14.16%
Disc Medicine
Nov 5, 2024
Maintains: Outperform
Price Target: $70 → $112
Current: $55.95
Upside: +100.18%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $70.07
Upside: +42.71%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $27.58
Upside: +30.53%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $5.68
Upside: -47.18%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $1,040.00
Upside: -61.92%